Indica Labs unveils AI-powered macrodissection tool for lung cancer
In a significant advancement for molecular pathology, Indica Labs has launched Lung Macrodissect AI, a novel tool designed to streamline slide macrodissection workflows. The announcement marks a pivotal step in integrating artificial intelligence with digital pathology.
Revolutionising tumour content estimation
Tumour content estimation and macro-dissection are crucial steps in molecular pathology, involving the assessment and isolation of tumour regions for downstream analysis. Traditional manual methods have been plagued by subjectivity, error-proneness, and lack of auditability. Lung Macrodissect AI addresses these challenges by quantifying tumour content across entire whole slide images and generating real-time information about tumour cell quantities within annotated regions.
Lung Macrodissect AI is seamlessly deployed in HALO AP, quantifies tumour content, streamlines tumour annotation, and ensures specimen quality for downstream analysis.
Enhanced accuracy and efficiency
The tool, which integrates seamlessly into Indica Labs’ HALO AP platform, offers several key features:
1. Quantification and standardisation of tumour content assessment
2. Streamlined macrodissection annotation for primary and metastatic non-small
cell lung cancer cases
3. Generation of tumour cell density heatmaps
4. Calculation of total tumour cells within regions of interest
5. Determination of tumour percentage
in all annotated regions.
Steven Hashagen, CEO of Indica Labs, commented: “We’re excited to offer pathologists an alternative to the current time-consuming, labour-intensive process of macrodissection. Our macrodissection AI models significantly advance the field of molecular pathology.”
Clinical validation demonstrates improved consistency
A clinical validation study involving 317 primary and metastatic whole slide images revealed significant improvements in agreement and consistency among pathologists when using Lung Macrodissect AI. The intraclass correlation coefficient (ICC) increased from 0.45 without AI assistance to 0.75 with AI assistance. Similarly, the Fleiss’ kappa statistic rose from 0.27 to 0.66 when using a 20% tumour content cut-off.
Peter Caie, Senior Principal Scientist in the AI Diagnostics group at Indica Labs, explained: “Lung Macrodissect AI advances the process of slide macrodissection by accurately and objectively quantifying every cell across a whole slide image, guiding and simplifying the anno-tation process and automatically reporting the tumour content within said annotation in real-time.”
Future developments and regulatory status
Indica Labs plans to expand its macrodissection tool suite to include models for colon, breast, and prostate cancers. Currently, Lung Macrodissect AI is not a medical device in the EU/UK and is not intended for diagnostic use. In the USA, it is for research use only and not FDA cleared for clinical diagnostic use.
For more information, visit:
https://indicalab.com/clinical-products/lung-macrodissect-ai/
Digital issue: Please click here for more information
